Investment Thesis
Rallybio is an early-stage biotech burning $29.8M annually with only $31.4M cash (approximately 1 year runway) against minimal $858K revenue. While the company boasts a strong balance sheet with no debt and improving loss metrics (net income improved 84.5% YoY), the operating losses of $33.1M vastly exceed revenue generation, indicating pre-commercial or very early-stage drug development with severe execution risk and likely need for dilutive financing within 12 months.
Strengths
- Strong balance sheet with $31.4M cash and zero debt
- Excellent liquidity position (14.50x current and quick ratios)
- Improving net loss trajectory (84.5% YoY improvement in net income)
- Revenue growing 34.9% YoY from early base
Risks
- Severe cash burn of $29.8M annually against minimal $858K revenue creates approximately 1-year runway
- Operating losses of $33.1M indicate pre-commercial stage with no clear path to profitability
- Extreme negative operating margin (-3853.6%) suggests significant R&D burn typical of biotech with high execution risk
- Will likely require dilutive equity financing within 12 months to extend runway
- Limited revenue visibility and commercial-stage drug data
Key Metrics to Watch
- Cash balance and quarterly burn rate trajectory
- Clinical trial progress and regulatory milestones for pipeline
- Revenue growth rate and product commercialization timeline
- Operating expense reduction and burn rate efficiency
- Financing announcements and potential dilution impacts
Financial Metrics
Revenue
858.0K
Net Income
-9.0M
EPS (Diluted)
$-1.59
Free Cash Flow
-29.8M
Total Assets
62.3M
Cash
31.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-3,853.6%
Net Margin
-1,046.4%
ROE
-15.5%
ROA
-14.4%
FCF Margin
-3,474.7%
Balance Sheet & Liquidity
Current Ratio
14.50x
Quick Ratio
14.50x
Debt/Equity
0.00x
Debt/Assets
6.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-09T20:00:31.458918 |
Data as of: 2025-12-31 |
Powered by Claude AI